



Suppl. Figure 4. FR-β expression by PV CD68+TAMs in localised human prostate tumors before and after ADT: correlation with tumor response. (A) CD68+ TAMs and (B) FR-β+CD68+ TAMs were predominantly PV both before and after patients received ADT (ie. matching samples). Tumors showing signs of CR (ie. starting to regrow within six months of ADT treatment - termed 'non-responders') were also compared to those that were still responsive to ADT (ie. hormone sensitive, 'HS' - termed 'responders'). Data are presented as means ± SEMs. * $p < 0.05$ and *** $p < 0.001$. 'ns' = not significant.